Skip to main content
. 2022 Oct 18;25(1):18–35. doi: 10.1111/dom.14863

FIGURE 1.

FIGURE 1

Key considerations for using once‐weekly subcutaneous semaglutide 2.4 mg in clinical practice (approved in Canada, Europe, the UK and the USA). 20 , 21 , 22 , 23 Abbreviations: AE, adverse event; GI, gastrointestinal; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist